ReviewDrug design, development and therapy2026

Precision Endocrine-Based Combinations After CDK4/6 Inhibitor Progression in HR-Positive Metastatic Breast Cancer.

Hikmat Abdel-RazeqPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.